Kornimate/medical-research-clean huggingface dataset:
visualization engineering platform for tcm pulse diagnosis - pulse diagnosis based on federated learning to diagnose slippery and choppy and other pulses waveform image features to assist in the study of tcm pathological logic analysis

Conditions: Slippery Pulse; Choppy Pulse

Summary: the diagnoses processes of traditional chinese medicine (tcm) focus on the following four main types of diagnoses methods consisting of inspection, olfaction, inquiry, and palpation. the most important one is palpation also called pulse diagnosis which is to measure wrist artery pulse by tcm doctor's fingers to detect patient's health state. the pulse diagnosis has three parts, namely 'chun', 'guan' and 'chy', with the location. wrist measurements correspond to different parts of the body's organs. in this project, it is to classify pulse types by using specialized pulse measuring instruments. the measured pulse wave (measured pulse wave, mpw) was segmented into arterial pulse wave curves (apwc) by the image suggestion method. the research object of this project is to collect and group patients diagnosed by traditional chinese medicine practitioners, namely slippery pulse, choppy pulse group and normal pulse control group, with at least 80 cases for each group. the research purpose of this project is mainly to carry out the visualization engineering platform of tcm pulse diagnosis - based on the pulse diagnosis of federated learning to diagnose the pulse waveform image features such as slippery pulse and choppy pulse to provide auxiliary tcm pathological logic analysis research and back-end cross-federal learning of tcm pulse diagnosis implementation of the node system. in other words, it is expected that the pulse wave characteristics measured by tcm physicians who cooperate with experts in the field can be collected from many tcm pulse diagnosis federated learning nodes, and analyzed by the multiple-expert repertory grid elicitation (merge) method. finally, the artificial intelligence model based on fl is trained to carry out tcm pathological logic analysis and related research. the results will be provided to tcm physicians as an important reference to assist clinical diagnosis.


Eligibility criteria:
inclusion criteria: 1. already sign test consent permit. 2. more than 20-year-old. exclusion criteria: 1. there is a wound or inflammation at the wrist skin measurement.

Keywords: artificial intelligence recurrent neural network wrist artery pulse diagnosis instrument tcm pulse diagnosis feature extraction
efficacy of ginger as an adjunctive prophylaxis for chemotherapy-induced nausea and vomiting

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: breast cancer patient receiving ac regimen chemotherapy (doxorubicin + cyclophosphamide) who has nausea score from 40/100 vas or vomiting after the first or second cycle of chemotherapy is recruited. the patient who meets the eligibility criteria and provides informed consent is randomised to receive either ginger capsule (500 mg) or placebo taking twice a day by mouth during the first 5 days of chemotherapy cycle. the study drug will be switched on the subsequent cycle (i.e. the patient who received ginger capsule will receive placebo and vice versa). the primary outcome is the nausea score and vomiting during the first 5 days of each chemotherapy cycle when receiving the study drug.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed breast cancer patient * received ac regimen chemotherapy (doxorubicin + cyclophosphamide) and has nausea score at least 40/100 vas or has vomiting * expect to receive at least 2 further cycles of ac regimen chemotherapy * provide informed consent exclusion criteria: * pregnancy or lactation * has nausea or vomiting during 24 hours before chemotherapy * has other causes of nausea or vomiting eg. brain metastasis, gut obstruction, hepatitis or recent abdominal or pelvic irradiation within 1 week before chemotherapy * received any chemotherapy regimen other than ac regimen * allergic or intolerance to ginger
feasibility of the integrative medication self-management intervention to promote medication adherence

Conditions: Medication Adherence; Chronic Disease

Summary: many persons with chronic health conditions fail to take their medications as prescribed, resulting in declines in health and function. unfortunately, current interventions for medication nonadherence are not very effective. this objective of this study is to test a new intervention, the integrative medication self-management (imeds) intervention to improve medication adherence in adults with chronic health conditions.

many persons with chronic health conditions fail to take their medications as prescribed, resulting in declines in health and function. objective: the purpose of this study was to perform a phase i feasibility study to understand if an integrated occupational therapy intervention could help people with chronic health conditions improve their adherence to medications. method: using a small-n design, we report single-subject analyses of the medication adherence, behavior counts, and perceptions of medication adherence of participants before and after either an occupational therapy intervention or standard of care intervention. we used a multiple baseline approach with inter-subject replication, and blinding.

Eligibility criteria:
inclusion criteria: * diagnosed with a chronic health condition * live in the community * a medication regimen of 5 or more medications a day recommended by a health care professional * independently manage medications * difficulty taking medications as prescribed * live in the milwaukee area exclusion criteria: * significant cognitive impairment

Keywords: occupational therapy medication adherence intervention studies
nexpowder to prevent delayed bleeding after endoscopic resection

Conditions: Gastro Intestinal Bleeding; Polyps

Summary: safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (nexpowder- endohs). indication: patients with indication of endoscopy resection by endoscopic mucal resection (emr) or endoscopic submucosal dissection (esd) with high risk of delayed bleeding (≥5%). hypotheses: the use of nexpowdertm after upper and lower gastrointestinal esd or emr of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.

hypotheses: the use of nexpowdertm after upper and lower gastrointestinal esd or emr of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%. study design: this is an investigator-initiated, multicentric, international, open-label, non-controlled, prospective study: * all subjects with indications undergo screening and baseline visit, * informed consent is obtained when scheduling the esd or emr procedure, * esd or emr is performed, at the end of resection, nexpowdertm is applied on the resected field, * a follow up visit is scheduled at 4 weeks. endpoints: * primary: * assess the delayed bleeding rate after esd or emr of ≥20mm in a selected high-risk population when using nexpowdertm at the end of the procedure. this hypothesis is that the use of nexpowdertm will reduce the rate of db from 16% (reported rate in the literature) to less than 5% (excepted observed rate during the study). * secondary: * safety of nexpowdertm endoscopic hemostasis system, * procedure duration and nexpowdertm spaying duration, * length of stay in hospital, * post intervention pain, * adverse events related to the use of nexpowdertm: * per procedural * early (up to controlled endoscopy or at 24hours post procedure) * late (up to 4 weeks follow-up).

Eligibility criteria:
inclusion criteria: * age: ≥18 year of age at the time of informed consent, * patients must have given written informed consent, * subjects with documented lesions with indication of upper or lower endoscopic removal by esd or emr with high risk of delayed bleeding (+/-16%), namely: * all patients under anticoagulation (vitamin k antagonist, direct anticoagulant, non-fractionated heparin or low molecular weight heparin) or anti-aggregating (p2y12 receptor antagonists), * patients without anticoagulation or anti-aggregating with indication of duodenal emr or esd (if duodenal cold snare emr: only under anticoagulant or p2y12 receptor antagonist), * resection field of esd or emr is ≥ 20mm (same size restriction in case of endoscopic papillectomy). exclusion criteria: * resection bed \<20mm, * subject currently enrolled in another interventional confounding research (no contra-indication for image or blood collection in another protocol), * incapacitated subjects, pregnant or lactating women.
cross-over study of sevelamer hydrochloride and sevelamer carbonate

Conditions: Chronic Kidney Disease

Summary: this is a double-blind, randomized, cross-over study conducted at centers within the united states. the study consists of five periods: an up to two-week screening period, a 5-week run-in period, two eight-week study treatment periods and a two-week washout period. patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks

the study was conducted at 15 centers (2 of which did not enroll any patients). a total of 79 hemodialysis patients were assigned randomly to one of two treatment sequences.

Eligibility criteria:
inclusion criteria: * patient had received hemodialysis three times per week for 3 months or longer; * patients were maintained on sevelamer hydrochloride as their primary phosphate binder with a total daily dose of ≤ 13.6 g with serum phosphorus concentrations at the last two measurements between 3.0 and 6.5 mg/dl, the most recent ipth ≤ 600 pg/ml and the most recent serum calcium within the normal range. exclusion criteria: * if patient had active bowel obstruction, dysphagia, swallowing disorders, or severe gastrointestinal motility disorders; * active ethanol or drug abuse (excluding tobacco); * need for antidysrhythmic or antiseizure medications used to control these conditions; * poorly controlled diabetes mellitus or hypertension; * active vasculitis; * active malignancy other than basal-cell carcinoma; * hiv infection; or * any clinically significant unstable medical condition as judge by the investigator.
320 multidetector computed tomography prior to coronary artery bypass surgery

Conditions: Coronary Disease

Summary: recent advances in technology have resulted in the development of scanners that can n image the heart arteries within 10 to 20 minutes but without the need for admission to hospital or insertion of catheters. this means that coronary heart disease may be more readily identified (or ruled out) and allow better diagnosis and treatment of patients with symptoms suggesting coronary heart disease. here, we propose to assess the latest and most powerful scanners to see if it can accurately diagnose the extent of coronary artery disease and facilitate the planning of heart surgery.


Eligibility criteria:
inclusion criteria: * patients who have undergone conventional coronary angiography and have been referred for coronary artery bypass surgery or valve replacement exclusion criteria: * age less than 18 * pregnancy or breast feeding * inability to undergo computed tomography scanning * inability to give informed consent * severe renal failure (serum creatinine \>250umol/l or estimated glomerular filtration rate \<15ml/min) * known allergy to iodinated contrast

Keywords: coronary disease coronary artery bypass cardiac surgery computed tomography coronary angiography
cardiometabolic risk in cardiac rehab

Conditions: Coronary Artery Disease

Summary: 1. primary objectives: * to characterize cardiometabolic risk factor profiles of patients entering cardiac rehab using traditional approaches (eg ldl-c) as well as a more comprehensive panel of cardiovascular and metabolic biomarkers. it is hypothesized that the comprehensive panel will identify further increased risk that would not have been detected using only traditional approaches. specifically, it is hypothesized that a greater percentage of the cohort will be identified with "high risk" levels of ldl-p (\>1100 nmol/l) and/or apob (\>80 mg/dl) than of ldl-c (\>100 mg/dl). it is further hypothesized that the prevalence of elevated lp(a) and elevated levels of inflammatory and insulin resistance markers will be higher in this cohort when compared to population norms (hdl, inc reference data). * to assess improvements in laboratory and lifestyle risk factors and rate of goal attainment at completion of rehab (eg 3 months). this objective is primarily descriptive, and improvements in traditional risk factors (eg ldl-c) will be compared to existing published data. improvements in non-traditional risk factors (eg ldl-p, insulin resistance markers) in a cardiac rehab population have not been extensively investigated. * to determine which attributes at baseline best predicted recurrent events and re-hospitalizations assessed one year later. 2. secondary/developmental objective: * to inform and guide development of a subsequent study protocol designed to compare outcomes associated with biomarker-guided personalized treatment plans vs. standard of care in the cardiac rehab setting.

this pilot study will characterize risk factors of patients as they enter cardiac rehab, track how comprehensive biomarker profiles change during the normal course of rehab, and associate biomarkers at baseline with mace outcomes assessed one year later. blood draws, vitals, and patient medical histories will be collected as subjects enter rehab and at the end of the rehab program. major adverse cardiac events will be assessed via phone interview at 12 months.

Eligibility criteria:
inclusion criteria: * known cad/ ihd * eligibility for cardiac rehab following an acute coronary event; either: * st elevation myocardial infarction * non st elevation myocardial infarction * angina * cabg exclusion criteria: * younger than 18 years old
atorvastatin and clopidogrel high dose in stable patients with residual high platelet activity

Conditions: Stable Angina

Summary: the purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity according to a point-of-care platelet function assay.

this is a prospective, randomized, open-label, control-active trial performed in elective patients candidates to coronary drug eluting stent implantation who presented high-on-treatment platelet reactivity, immediately before coronary intervention (pci). all patients are treated with aspirin (100 mg/day) and standard-dose clopidogrel (600 mg as loading dose and 75 mg daily as maintenance dose)for at least 7 days before pci. platelet function is assessed by the verifynow p2y12 assay (accumetrics, san diego, ca). patients are eligible to be enrolled if they have high-on-treatment reactivity defined as p2y12 reaction units (pru) \>= 230, immediately before pci. after pci, patients are randomized to receive high-dose clopidogrel (150 mg daily) or high-dose atorvastatin (80mg/day) + high-dose clopidogrel (150 mg daily). study visits and platelet function testing with the verifynow p2y12 test are conducted at 7 and 30 days after randomization.

Eligibility criteria:
inclusion criteria: * stable angina * candidates to drug eluting stent implantation * high on-treatment platelet reactivity according to a point-of-care platelet function test exclusion criteria: * chronic therapy with statins * inability to provide informed consent * intolerance to statins * acute or chronic liver failure or alt \> 2 times uln * known myopathy * ckd stage iv or dialysis treatment * pregnancy or breast-feeding * malignancy

Keywords: clopidogrel statins platelet reactivity point-of-care platelet function test
diabetes and hypertension self management program

Conditions: Diabetes Mellitus, Type 2; Hypertension

Summary: the purpose of this r15 project is to test the feasibility and effectiveness of a 12-week diabetes and hypertension self-management program using trained health coaches.

west virginia has high prevalence of comorbid diabetes and hypertension. most diabetes self-management programs are hospital or clinic based and none are tailored to address the unique needs of rural wv adults with comorbid diabetes (t2dm) and hypertension (htn). there is a critical need for new and creative community-based, culturally appropriate self-management programs in this medically underserved state. this study will use a wait-listed randomized control trial (rct) design, using evidence-based interventions, to improve patient self-management behaviors and health outcomes (hba1c and bp). eligible adults with comorbid t2dm and htn will be randomized with a 1:1 ratio to the immediate diabetes and hypertension self-management program (dhsmp; n=35) or to 6-month wait-listed control group (n=35), based on an allocation sequence generated by the biostatistician using a randomly varying block randomization method to ensure equal distribution among treatment groups.

Eligibility criteria:
inclusion criteria: * english speaking adults \>= 18 years of age; * co-occurring diagnosis of t2dm and htn; * body mass index \>= 25.0 * willing to be randomized and complete all assessments. exclusion criteria: * currently pregnant or breastfeeding; * diagnosed with a severe mental illness; * have any condition that requires physical activity limitations or is contraindicated for the dietary assessment to stop hypertension (dash) diet; * inability to complete the study protocol.
hiv&heart aging study (12,5 year follow up)

Conditions: HIV Infections; Coronary Disease; Myocardial Infarction; HIV Encephalopathy; Aging; Heart Failure

Summary: the hiv/heart aging study (hivh) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (cvd) in hiv-infected patients. the study population includes outpatients from specialized hiv-care units of the german ruhr region, who were at least 18 years of age, were known to have a hiv-infection and exhibited a stable disease status within 4 weeks before inclusion into the trial. from march 2004 (pilot phase) to october 2019 (12,5 year follow-up) 1806 hiv+ patients were recruited in a consecutive manner. the standardised examinations included a targeted assessment of medical history and physical examination. blood was drawn for comprehensive laboratory tests including hiv specific parameters (cd4 cell count, hiv-1 rna levels) and cardiovascular items (lipid concentrations, bnp values and renal parameters). furthermore, non-invasive tests were performed during the initial visit, including additional heart rate and blood pressure measurements, electrocardiogram (ecgs) and transthoracic echocardiography (tte). examinations were completed in accordance with previously defined standard operating procedures. cvd were defined as coronary, cerebrovascular, peripheral arterial disease, heart failure or cardiac vitium.

a comprehensive detailed description of the study procedures had been previously published (european journal of medical research 2007;12:243-248). comprehensive non invasive cardiovascular examination * anamnesis * file recherche,physical examination * documentation of the cardiovascular and antiretroviral medical therapy * electrocardiogram * transthoracic echocardiography * exercise electrocardiogram * exercise montreal cognitive assessment test * exercise the grooved pegboard test * blood collection * questionnaire to quality of life and health economics

Eligibility criteria:
inclusion criteria: * age \> 18 years * known hiv-infection * signed informed consent exclusion criteria: * acute cardiovascular disease * unstable hemodynamic status in the three weeks before inclusion * pregnancy

Keywords: hiv aids antiretroviral therapy aging heart failure coronary heart disease myocardial infarction hiv-associated neurocognitive disorders
diaphragmatic breathing training on postpartum anxiety

Conditions: Postpartum Anxiety

Summary: this is a two-group pretest-posttest, triple-blinded and randomized controlled trial examining the effects of a biofeedback-assisted diaphragmatic breathing training on postpartum anxiety. this study will include full-term postpartum women, aged from 20 to 49, who experienced anxious symptoms with state anxiety inventory (a-state) scored 40 or more at the first postpartum day. participants will be randomly assigned to either an experimental group (n = 64) or a control group (n = 64). the experimental group will undergo the diaphragmatic breathing training assisted with stresseraser to breath slowly 4-6 times per minute and practice 15 minutes twice daily. participants in the control condition receive postpartum usual care. the outcome measures include anxiety measured by state-trait anxiety inventory (stai) and the physiological parameters expressed by blood pressure (bp) and heart rate (hr). measurements will be taken at the first postpartum day and one month postpartum. we except this breathing training design is able to improve women's postpartum anxiety, and in turn improve their physio-psychological health, breastfeeding and baby care skills.

ditto

Eligibility criteria:
inclusion criteria: * full-term postpartum women * aged from 20 to 49 * stai-s scored 40 or more at the first postpartum day exclusion criteria: * newborn with severe illness or stillbirth * maternal suicide or self-harm * drug use: sedatives, hypnotics or antipsychotic drugs

Keywords: postpartum anxiety biofeedback diaphragmatic breathing
circulating cell-free tumor dna in the plasma of patients with gastrointestinal stromal tumors (gist)

Conditions: Gastrointestinal Stromal Tumor (GIST)

Summary: this observational study is proposed to evaluate if the trend in the levels of cf-dna evaluated on a sample of peripheral blood may be related to different clinical behaviors of the disease monitored by radiological investigations conducted.

demetri and colleagues presented, at the aacr and asco annual meeting 2013, an exploratory analysis to assess gist genotypes on patients in the grid study. mutations in the kit gene were detected in 58 percent of the blood samples compared with 66 percent of the tumor tissue samples (31). however, when focusing their analysis on secondary kit mutations, which are the mutations that drive resistance to targeted therapies like imatinib and sunitinib, the researchers found mutations in 47 percent of blood samples compared with only 12 percent of tissue samples. in addition, nearly half of blood samples in which secondary kit mutations were found, harbored multiple secondary mutations. therefore, cf-dna may become an efficient marker of mutational gist status and disease itself. on this basis, this trial aims to evaluate whether tumor dna carrying mutations (for kit, pdgfrα, braf, ras, sdh) can be detected and quantified in the plasma of patients with gists, either with active disease or during follow-up, and whether detection can be correlated with the disease status.

Eligibility criteria:
* male or female patients aged \>= 18 years * histologically confirmed diagnosis of gist of any anatomical location either by biopsy or surgical specimen * available archival tumor tissue * signed informed consent form exclusion criteria: * impossibility to ensure adequate clinical and serum sample follow-up * serious psychiatric disease that precludes informed consent or limits compliance